The Potential of Epigallocatechin Gallate in Targeting Cancer Stem Cells: A Comprehensive Review

Overview

Journal Curr Med Chem

Publisher Bentham Science Publishers

Specialty Chemistry

Date 2024 Jan 20

PMID 38243984

Authors

Rupa Chaudhuri

Anurima Samanta

Priyanka Saha

Sukanya Ghosh

Dona Sinha

Affiliations

Soon will be listed here.

Abstract

The dreadful scenario of cancer prevails due to the presence of cancer stem cells (CSCs), which contribute to tumor growth, metastasis, invasion, resistance to chemo- and radiotherapy, and recurrence. CSCs are a small subpopulation of cells within the tumor that are characterized by self-renewal capability and have the potential to manifest heterogeneous lineages of cancer cells that constitute the tumor. The major bioactive green tea polyphenol (-)-epigallocatechin gallate (EGCG) has been fruitful in downgrading cancer stemness signaling and CSC biomarkers in cancer progression. EGCG has been evidenced to maneuver extrinsic and intrinsic apoptotic pathways in order to decrease the viability of CSCs. Cancer stemness is intricately related to epithelial-mesenchymal transition (EMT), metastasis and therapy resistance, and EGCG has been evidenced to regress all these CSC-related effects. By inhibiting CSC characteristics EGCG has also been evidenced to sensitize the tumor cells to radiotherapy and chemotherapy. However, the use of EGCG in and cancer models raises concern about its bioavailability, stability and efficacy against spheroids raised from parental cells. Therefore, novel nano formulations of EGCG and adjuvant therapy of EGCG with other phytochemicals or drugs or small molecules may have a better prospect in targeting CSCs. However, extensive clinical research is still awaited to elucidate a full proof impact of EGCG in cancer therapy.

Citing Articles

Phytochemicals as Therapeutic Agents against Cancer.

Chandra Bharti A Curr Med Chem. 2024; 31(32):5111-5112.

PMID: 39234775 DOI: 10.2174/092986733132240708114243.

From mechanism to therapy: the journey of CD24 in cancer.

Zhao K, Wu C, Li X, Niu M, Wu D, Cui X Front Immunol. 2024; 15:1401528.

PMID: 38881902 PMC: 11176514. DOI: 10.3389/fimmu.2024.1401528.

References

Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Minden M . A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994; 367(6464):645-8. DOI: 10.1038/367645a0. View

Visvader J, Lindeman G . Cancer stem cells: current status and evolving complexities. Cell Stem Cell. 2012; 10(6):717-728. DOI: 10.1016/j.stem.2012.05.007. View

Greene R, Pisano M . Palate morphogenesis: current understanding and future directions. Birth Defects Res C Embryo Today. 2010; 90(2):133-54. PMC: 3138490. DOI: 10.1002/bdrc.20180. View

Zhou B, Zhang H, Damelin M, Geles K, Grindley J, Dirks P . Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov. 2009; 8(10):806-23. DOI: 10.1038/nrd2137. View

Fujiki H, Watanabe T, Sueoka E, Rawangkan A, Suganuma M . Cancer Prevention with Green Tea and Its Principal Constituent, EGCG: from Early Investigations to Current Focus on Human Cancer Stem Cells. Mol Cells. 2018; 41(2):73-82. PMC: 5824026. DOI: 10.14348/molcells.2018.2227. View

Gan R, Li H, Sui Z, Corke H . Absorption, metabolism, anti-cancer effect and molecular targets of epigallocatechin gallate (EGCG): An updated review. Crit Rev Food Sci Nutr. 2016; 58(6):924-941. DOI: 10.1080/10408398.2016.1231168. View

Cione E, La Torre C, Cannataro R, Caroleo M, Plastina P, Gallelli L . Quercetin, Epigallocatechin Gallate, Curcumin, and Resveratrol: From Dietary Sources to Human MicroRNA Modulation. Molecules. 2019; 25(1). PMC: 6983040. DOI: 10.3390/molecules25010063. View

Chung S, Vadgama J . Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFκB signaling. Anticancer Res. 2015; 35(1):39-46. PMC: 4290892. View

Rather R, Bhagat M . Cancer Chemoprevention and Piperine: Molecular Mechanisms and Therapeutic Opportunities. Front Cell Dev Biol. 2018; 6:10. PMC: 5818432. DOI: 10.3389/fcell.2018.00010. View

10.

Appari M, Babu K, Kaczorowski A, Gross W, Herr I . Sulforaphane, quercetin and catechins complement each other in elimination of advanced pancreatic cancer by miR-let-7 induction and K-ras inhibition. Int J Oncol. 2014; 45(4):1391-400. PMC: 4151818. DOI: 10.3892/ijo.2014.2539. View

11.

Chen D, Pamu S, Cui Q, Chan T, Dou Q . Novel epigallocatechin gallate (EGCG) analogs activate AMP-activated protein kinase pathway and target cancer stem cells. Bioorg Med Chem. 2012; 20(9):3031-7. PMC: 3334407. DOI: 10.1016/j.bmc.2012.03.002. View

12.

Fujiki H, Suganuma M, Imai K, Nakachi K . Green tea: cancer preventive beverage and/or drug. Cancer Lett. 2002; 188(1-2):9-13. DOI: 10.1016/s0304-3835(02)00379-8. View

13.

Granja A, Pinheiro M, Reis S . Epigallocatechin Gallate Nanodelivery Systems for Cancer Therapy. Nutrients. 2016; 8(5). PMC: 4882719. DOI: 10.3390/nu8050307. View

14.

Andreu-Fernandez V, Toledano L, Pizarro N, Navarro-Tapia E, Gomez-Roig M, de la Torre R . Bioavailability of Epigallocatechin Gallate Administered With Different Nutritional Strategies in Healthy Volunteers. Antioxidants (Basel). 2020; 9(5). PMC: 7278615. DOI: 10.3390/antiox9050440. View

15.

Shirakami Y, Shimizu M . Possible Mechanisms of Green Tea and Its Constituents against Cancer. Molecules. 2018; 23(9). PMC: 6225266. DOI: 10.3390/molecules23092284. View

16.

Wang L, Li P, Feng K . EGCG adjuvant chemotherapy: Current status and future perspectives. Eur J Med Chem. 2023; 250:115197. DOI: 10.1016/j.ejmech.2023.115197. View

17.

Farabegoli F, Pinheiro M . Epigallocatechin-3-Gallate Delivery in Lipid-Based Nanoparticles: Potentiality and Perspectives for Future Applications in Cancer Chemoprevention and Therapy. Front Pharmacol. 2022; 13:809706. PMC: 9046542. DOI: 10.3389/fphar.2022.809706. View

18.

Eng Q, Thanikachalam P, Ramamurthy S . Molecular understanding of Epigallocatechin gallate (EGCG) in cardiovascular and metabolic diseases. J Ethnopharmacol. 2017; 210:296-310. DOI: 10.1016/j.jep.2017.08.035. View

19.

Feng W . Metabolism of green tea catechins: an overview. Curr Drug Metab. 2006; 7(7):755-809. DOI: 10.2174/138920006778520552. View

20.

Li C, Lee M, Sheng S, Meng X, Prabhu S, Winnik B . Structural identification of two metabolites of catechins and their kinetics in human urine and blood after tea ingestion. Chem Res Toxicol. 2000; 13(3):177-84. DOI: 10.1021/tx9901837. View